Vivos Therapeutics Reports 212% Jump in Nevada Sleep Apnea Patient Referrals

Key Points

• New sleep apnea patient referrals at Vivos’ Nevada centers increased 212% over the latest six-week period compared with the prior six weeks.
• Average weekly referrals across the Las Vegas market have risen nearly fivefold since June 1, according to the company.
• Vivos is opening a new 8,100-square-foot sleep diagnostic, testing, and treatment center in Henderson, Nevada.
• The new center replaces a smaller facility and is intended to expand patient-testing and treatment capacity.
• The prior Henderson practice generated record total collections in two of the past three months.
• Management expects the capacity expansion to support near-term Las Vegas-market revenue growth, though it has not issued a specific forecast.

Vivos Therapeutics (NASDAQ: VVOS) reported a 212% increase in new obstructive sleep apnea patient referrals at its Nevada Sleep & Airway Medicine Centers, highlighting rapidly growing demand for sleep testing and treatment services in the Las Vegas market. The company is expanding capacity with a new 8,100-square-foot Henderson facility scheduled to open on August 27, 2026.

Rapid Nevada Referral Growth Increases Demand for Vivos Sleep Apnea Services

Vivos said new obstructive sleep apnea referrals at its Nevada Sleep & Airway Medicine Centers climbed 212% in the most recent six-week period. It also reported that weekly referral volume in the Las Vegas market has increased nearly fivefold since June 1.

This is a positive early demand indicator for Vivos’ sleep-apnea business. A larger referral pipeline could lead to more patient consultations, diagnostic sleep studies, and treatment plans. However, referrals do not automatically become revenue; financial performance will depend on patient scheduling, insurance coverage, testing completion, treatment acceptance, reimbursement, and collection rates.

New Henderson Sleep Center Adds Capacity for Testing and Treatment

To accommodate stronger demand, Vivos is opening an 8,100-square-foot sleep diagnostic, testing, and treatment center in Henderson on August 27, 2026. The site replaces a smaller local practice and is expected to serve as a larger hub for patients in the Las Vegas metropolitan area.

The expanded facility will provide sleep testing and treatment services for obstructive sleep apnea and related conditions. Vivos said the location is designed to streamline the patient experience by allowing patients to receive comprehensive diagnostic services and begin individualized treatment more efficiently.

Expanded Las Vegas Operations Could Improve Vivos Revenue Potential

Vivos said the new facility’s added capacity should allow it to manage higher referral volumes and may have an immediate impact on revenue in the Las Vegas market. The former Henderson location recorded its highest total collections in two of the prior three months, suggesting improving local demand and patient conversion before the larger facility opened.

The potential upside is straightforward: more available appointment slots and testing capacity could help the company see more patients and provide more treatments. The key execution challenge will be expanding volume while controlling staffing, marketing, facility, and other operating costs.

What VVOS Investors Should Watch as Nevada Operations Scale

The 212% referral increase offers a constructive sign of demand, but investors should focus on how well Vivos converts these referrals into realized revenue and sustainable margins. Important measures include new patient visits, sleep-study completion rates, treatment-plan acceptance, revenue per patient, reimbursements, collections, center operating expenses, and cash flow.

The Henderson expansion gives Vivos a concrete opportunity to grow its Nevada sleep-apnea services platform. Long-term value will depend on sustained referral momentum, disciplined cost management, successful treatment conversion, and evidence that the larger facility can deliver profitable growth rather than only higher operating expenses.